MPM BioImpact’s Werewolf Therapeutics HOWL Stock Holding History

MPM BioImpact’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.9K	Sell	80,142 -1,128,668	-93%	-$688K	﹤0.01%	37
2026 Q1	$1.01M	Sell	1,208,810 -184,747	-13%	-$127K	0.08%	41
2025 Q4	$884K	Sell	1,393,557 -1,015,253	-42%	-$1.23M	0.1%	38
2025 Q3	$4.75M	Hold	2,408,810	–	–	0.78%	31
2025 Q2	$2.63M	Hold	2,408,810	–	–	0.45%	40
2025 Q1	$2.34M	Buy	2,408,810 +20,799	+0.9%	+$27.2K	0.4%	39
2024 Q4	$3.53M	Hold	2,388,011	–	–	0.5%	41
2024 Q3	$5.06M	Hold	2,388,011	–	–	0.76%	37
2024 Q2	$5.83M	Hold	2,388,011	–	–	0.91%	36
2024 Q1	$15.5M	Hold	2,388,011	–	–	2.49%	11
2023 Q4	$9.22M	Hold	2,388,011	–	–	2.16%	20
2023 Q3	$5.11M	Hold	2,388,011	–	–	1.36%	24
2023 Q2	$7.28M	Hold	2,388,011	–	–	1.47%	21
2023 Q1	$6.21M	Hold	2,388,011	–	–	1.61%	18
2022 Q4	$4.9M	Hold	2,388,011	–	–	1.27%	19
2022 Q3	$10.8M	Hold	2,388,011	–	–	2.55%	12
2022 Q2	$9.77M	Hold	2,388,011	–	–	2.71%	10
2022 Q1	$10.5M	Hold	2,388,011	–	–	2.82%	7
2021 Q4	$28.4M	Hold	2,388,011	–	–	5.19%	6
2021 Q3	$41M	Hold	2,388,011	–	–	6.36%	4
2021 Q2	$41.6M	Buy	+2,388,011	New	+$32.7M	6.84%	6

Other funds holding HOWL

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

Verdad Advisers Boston, Massachusetts $104M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MPM BioImpact's HOWL Position: Q2 2026 in Review

MPM BioImpact reduced its Werewolf Therapeutics (HOWL) stake by 93% in Q2 2026, selling an estimated $688K and leaving 80,142 shares worth $28.9K. The position accounts for ﹤0.01% of the portfolio, ranked #37.

MPM BioImpact first reported a position in HOWL in Q2 2021 and has held it in 21 quarters since. The position peaked at $41.6M in Q2 2021. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

MPM BioImpact held 80,142 shares of Werewolf Therapeutics worth $28.9K as of Q2 2026.
MPM BioImpact sold 1,128,668 Werewolf Therapeutics shares in Q2 2026, an estimated $688K.
Werewolf Therapeutics made up ﹤0.01% of MPM BioImpact's portfolio in Q2 2026, its #37 holding.
MPM BioImpact first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 21 quarters since.
MPM BioImpact's Werewolf Therapeutics position peaked at $41.6M in Q2 2021.
45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.